Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Return on Sales (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Return on Sales for 7 consecutive years, with 70.95% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 3649.0% year-over-year to 70.95%, compared with a TTM value of 32.16% through Dec 2025, down 260.0%, and an annual FY2025 reading of 36.4%, down 685.0% over the prior year.
  • Return on Sales was 70.95% for Q4 2025 at Avidity Biosciences, down from 13.95% in the prior quarter.
  • Across five years, Return on Sales topped out at 8.82% in Q1 2021 and bottomed at 73.32% in Q1 2025.
  • Average Return on Sales over 5 years is 27.02%, with a median of 20.51% recorded in 2023.
  • Peak annual rise in Return on Sales hit 2036bps in 2025, while the deepest fall reached -5392bps in 2025.
  • Year by year, Return on Sales stood at 20.78% in 2021, then grew by 12bps to 18.22% in 2022, then crashed by -51bps to 27.51% in 2023, then dropped by -25bps to 34.46% in 2024, then tumbled by -106bps to 70.95% in 2025.
  • Business Quant data shows Return on Sales for RNA at 70.95% in Q4 2025, 13.95% in Q3 2025, and 40.72% in Q2 2025.